Miami Beach

Drug Discovery Targets Cancer Vulnerabilities

Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.

May 20, 2016
Dr Michel Sadelain AACR

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016
MRSA  Photo Credit: Public Health Image Library (PHIL)

Can ADCs be adapted to tackling MRSA?

Can we use technological approaches from oncology to applying creative ways to treating bacterial infections?

April 27, 2016
Lemons Villa Borghese

Targeting Acquired Resistance in Prostate Cancer

The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.

April 4, 2016
Prof Qasim ASH 2015 poster

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015
Prof Qasim UCART19 ASH 2015 Poster

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015
Cindy Chew 9/5/11Hauser

Is ocrelizumab a game changer in MS?

At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.

October 11, 2015
Vienna Torte

Novel Targets Podcast 6 – Immune Agonists

What happens when we literally step on the gas with immune agonists?

September 24, 2015
ECC 2015 Go the Extra Mile

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015
Chicago City View

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015
Boston Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015
Syros Website Screenshot

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015
Liverpool waterfront

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging

January 12, 2015

Biotech Strategy Blog – the year of the paywall

Thank you to all our subscribers for a great year!

September 17, 2014
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
BJTC Award 2014 Final

Healthcare Innovation in Action: Designing for Dementia

Can design make a difference to those with dementia? Liverpool City Council's award-winning Sedgemoor Dementia Support Centre shows how design innovation can stimulate memories and offer improved quality of life.

April 28, 2014
Everton in the Community

Everton FC leads the way in community dementia support

Everton FC and Mersey Care NHS Trust use football memorabilia and activities at Goodison Park to stimulate memories and support members of the local community with dementia.

April 23, 2014
Source: Roche

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
CAR T Cells

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
FDA Cancer Related NME Approvals 2012

2012 was a Grand Cru year for the FDA with 39 NMEs approved

FDA approved 39 new molecular entities in 2012. This is the highest number in the last 10 years. However, approval rate is not a surrogate benchmark for the state of innovation given that it can take several years to bring a new drug or biologic to market.

January 2, 2013
Early bionic eye prototype drawing - Image courtesy of Bionics Institute

Innovation in Action: helping people to see again

FDA approves first artificial retina prosthesis, the Argus II from Second Sight. This is not a bionic eye. To date, only crude images can be detected. There is no dramatic restoration of sight or vision, instead retinal prostheses currently only offer the ability to detect light and large shapes. Several companies and research groups including Bionic Vision Australia are working on innovative retinal prostheses that aim to restore some vision.

September 17, 2012
Credit: Caltech and Harvard University

Creating an artificial jellyfish to model the human heart

Creation of an artificial jellyfish advances the potential to reverse engineer the human heart

August 20, 2012

The Potential of Gene Therapy to Restore Hearing Loss

Restoration of hearing in mice by gene transfer is a major breakthrough

August 14, 2012
Science Translational Medicine Cover May 16

Repetitive brain injury from high impact sports generates similar pathophysiology to traumatic brain injury in soldiers blown up by IEDs

Several retired American Football stars have ended up with chronic traumatic encephalophy (CTE). It’s similar to Alzheimer’s disease in that the brain ends up with neurofibrillary tangles. CTE has also been seen in soldiers who have experienced blast induced traumatic brain injury (bTBI) from improvised explosive devices (IEDs)

May 21, 2012
Drug Development Pipeline

TEDMED 2012: Francis Collins on how to brings drugs to market faster

It can take 14 years of research and the screening of 10,000 compounds to bring 1 new drug to market.

May 18, 2012
Participant S3 drinking froma bottle using the DLR robotic arm

Innovation in Neurotechnology: how a paralyzed person uses thoughts to control a robotic arm

A tetraplegic (all four limbs paralyzed) is able to use her mind to control a robotic arm, 15 years after she became completely paralyzed & unable to speak.

May 16, 2012
Winter in Malta

A personal perspective on Alzheimer’s: my mother doesn’t dance anymore

I have a personal interest in Alzheimer’s disease. It’s an area where innovation needs to catch up with demand for treatment and therapies, not to treat it when it’s happened – it’s too late to untangle the damage, but to delay it’s occurrence in those at risk.

March 9, 2012
MicroCHIPS Drug Delivery Device

Implanted Wireless Microchip offers Osteoporosis Drug Delivery that improves patient Quality of Life

Robert Farra of MicroCHIPS, Inc. and research collaborators, describe a first-in-human testing of a wirelessly controlled drug delivery microchip.

February 20, 2012
Children's Hospital Boston Innovation Acceleration Program

Today is Innovation Day at Childrens Hospital Boston #iDay

Children’s Hospital Boston has an Innovation Acceleration Program focused on supporting “clinical care that impacts patients around the world.”

February 14, 2012

Blocking Sema4D may be a new osteoporosis target

Research published in the November 2011 issue of the journal Nature Medicine has highlighted a new potential target for osteoporosis drug development that acts on osteoblasts and promotes bone formation.

November 10, 2011

Discovering the cause of Lou Gehrig’s disease

Scientists from Northwestern University in Chicago report findings that could help develop drugs for patients with Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s disease.

August 31, 2011

Can we halt memory loss as we get older?

New research offers the hope that in the future we may be able to reverse or slow-down the age-related memory loss and cognitive defects we would otherwise experience.

August 26, 2011

Innovation – should companies take bigger risks and outsource pharma R&D?

"Rather than do research in house, companies should close their labs and outsource the work to tiny, nimble startups that can explore bigger, crazier ideas.”

August 3, 2011

How we may be able to rebuild The Six Million Dollar Man

The Six Million Dollar Man was fiction, but it is becoming closer to reality as a result of new research into how artificial limbs can integrate with human tissues

July 11, 2011
Miami Beach

How does sunburn cause pain?

Research by John Dawes and colleagues at King’s College London & University College London has shed new light on how sunburn causes pain.

July 8, 2011

Regenerative Medicine: Tissue Engineered Airway Transplant

Researchers from University College London led by Prof. Alexander Seifalian designed and built a polymer based nanocomposite tracheal scaffold, which was then seeded with the patient’s own stem cells.

July 7, 2011

Science Translational Medicine on Innovation – part 1

With an image of Rodin’s bronze “The Thinker” on its cover suggesting deep thought and insight, the journal "Science Translational Medicine" analyzes the state of innovation.

July 7, 2011

Will the future offer artificial retina transplants?

A Nature article shows, for the first time, the ability to generate a three-dimensional culture of neural retinal tissue from mouse embryonic stem (ES) cells.

April 29, 2011

The future of Parkinson’s disease, part 2 of an interview with Dr Todd Sherer, Chief Program Officer, Michael J Fox Foundation

"The understanding of the genetics of Parkinson’s will certainly form the building blocks of some future breakthroughs. Now that we have very tangible therapeutic targets that we know can cause Parkinson’s, it makes a much more rational directed drug development program."

April 8, 2011

Making a difference to Parkinson’s Disease Research, an interview with Dr Todd Sherer, Michael J Fox Foundation

"The goal of the foundation, the goal of all the research that we are supporting is to develop new therapies for Parkinson’s disease patients."

March 31, 2011

Of Mice and Men

The March 17, 2011 edition of Nature, highlights how innovative preclinical animal models are having an impact on drug development.

March 25, 2011
EAU 2011 Vienna

Technology Innovation – the challenges and opportunities with robotic surgery

At the European Association of Urology (EAU) annual congress in Vienna, Associate Professsor Axel Merseburger from Hannover in Germany discussed some of the challenges with robotic surgery for prostatectomy or partial nepthrectomy.

March 19, 2011
LLNL Artificial Retina Video Screen Shot

Argus III is the next generation of artificial retina from Lawrence Livermore National Laboratory

Lawrence Livermore National Laboratory (LLNL) have produced an excellent video about their manufacturing of the Argus™ III artificial retina.

March 14, 2011

Artificial Retina Project shows power of collaboration to bring new products to market

The Artificial Retina Project is a case study on the success of collaboration.

March 14, 2011
second sight logo

New artificial retina restores some visual perception and improves autonomy

Detecting a door or a window may not be a big deal for all of us with normal vision, but for those who lose their sight, e.g. through retinitis pigmentosa (RP), a new "artificial retina" now provides hope of a better quality of life.

March 8, 2011
romosozumab NEJM press release

Targeting Sclerostin in Osteoporosis

Sclerostin is a protein produced by osteocytes within bone that inhibits bone formation. It is thought to pass through the surface of bone where it acts on osteoblasts (cells responsible for bone formation). There it binds to low-density lipoprotein receptors and inhibits the Wnt/beta-catenin signaling involved in bone mass regulation. Promising phase 2 trial data for a novel sclerostin inhibitor, romosozumab (AMG 785), in osteoporosis has just been published in the New England Journal of Medicine.

March 10, 2011

Merck’s cathepsin-K inhibitor odanacatib in osteoporosis

Cathepsin-K inhibition is a novel approach to osteoporosis treatment and Merck's odanacatib is leading the way in this new class of drugs.

February 11, 2011
Nature Reviews Drug Discovery

Emerging drugs in development for Osteoporosis

The market opportunity for osteoporosis remains significant, affecting 44 million people in the United States over the age of 50, resulting in healthcare costs in excess of $15 billion a year.

February 8, 2011

New research points to role of Cystic Fibrosis Transmembrane Conductance Regulator Signaling in Emphysema

Developing drugs that target cystic fibrosis transmembrane regulator (CFTR) protein and mediate ceramide may have an important role to play in the treatment of emphysema

January 10, 2011